Few examples of these systems in current clinical trials include SGT‐53, which has shown success in restoring function of human suppressor gene p53 by delivering a plasmid containing wild‐type p53 sequence.62 The implications of this technology are immense, as p53 dysfunction is present in most cancers63 and is believed to be a requirement for tumor growth64; as such, technologies restoring its proper function can potentially be used to treat a number of cancers. This evidence concerns the gene TP53 and neoplasm.